2-Amino-5-iodopyridine, CAS 20585-15-5, molecular formula C₅H₅IN₂ and molar mass 220.01 g·mol^-1, is supplied as a pharma grade heterocyclic amine building block and, where a national filing or monograph authorization exists, as an active substance for oral solid and injectable dosage forms. The molecule is a 2-aminopyridine derivative in which the iodine atom at position 5 creates a heavy-atom effect: greater molecular density, higher polarizability, and stronger UV absorption than the 5-chloro and 5-bromo homologues. For tablet, capsule, granule, and injection manufacture, the relevant technical grades differ by particle engineering, microbial burden, and container-closure history. Supplier model codes commonly distinguish a crystalline powder, a jet-milled low-D90 grade for dry powder capsule filling, a compacted granular grade for direct compression, and a sterile powder for aseptic filling. These designations are supplier-specific and are not harmonized by Ph. Eur. or USP monographs. Because no harmonized final API monograph exists for this substance, release data must be anchored to supplier specifications, ICH Q3C residual solvent limits, ICH Q3D elemental impurity risk assessment, and pharmacopeial general chapters for the intended dosage form. Published formulation data for this specific configuration is limited; process suitability must be demonstrated with the actual batch under current GMP.

When the Material Enters Direct Compression, Dry Granulation, or Capsule Filling

The free base is a low-molecular-weight crystalline solid with an expected brittle fracture tendency under compression stress. Direct compression performance therefore depends more on particle engineering, particle size distribution, and moisture control than on intrinsic plastic deformation of the molecule. In rotary tablet press operation, segregation and die-fill variability are reduced by granulated intermediates or by adding a dry binder. If direct compression is unavoidable, the API is often blended with microcrystalline cellulose, pregelatinized starch, and a glidant such as colloidal silicon dioxide at 0.25% w/w to 0.50% w/w. Higher glidant concentrations do not automatically improve flow and may lower blend uniformity because fine silica particles migrate during prolonged mixing.

For roller compaction, ribbon density and granule D10/D50/D90 are more useful than roll force alone. Ribbon density is compared with the target established from compactability tests using the actual formulation; if the milled granule D50 shifts by more than 10–15% between development batches, roll gap, roll force, and screen size are adjusted. Capsule filling on tamping-pin or dosator equipment requires control of powder bed height and pin compression settings; blend bulk density should be measured after every scale-up step. Blend uniformity testing is typically performed by HPLC endpoint assay and is interpreted with USP <905> uniform dosage unit criteria, not solely by supplier certificate of analysis.

Wet granulation in a high-shear mixer may produce local overheating and moisture pockets if chopper and impeller speeds are not optimized. The 2-amino group can interact with reducing sugars through Maillard-type browning; therefore lactose monohydrate, microcrystalline cellulose, and pregelatinized starch are generally preferred over reducing-sugar fillers unless forced degradation studies demonstrate compatibility. Drying is performed immediately after wet massing. Loss on drying by USP <731> and water content by Karl Fischer USP <921> Method Ic are used to confirm residual moisture. Because published data for this specific configuration is limited, the dryer inlet air temperature and the final moisture limit are set from stability data for the formulation rather than from a universal API specification. When tableting is performed on a high-speed rotary press, pre-compression force, main compression force, and turret speed are adjusted to the granulation’s compressibility. If water content exceeds 1.0% w/w, a pre-drying step at 40–50 °C may be introduced; the pressing area should also be maintained below 60% RH to limit punch sticking.

Why Does the Heavy Halogen Increase Segregation and Analytical Interference?

The iodine atom at position 5 increases molecular mass and can produce crystals with a density above many common fillers, which raises segregation risk during hopper discharge and transfer line vibration. If the API is milled to a D90 below 45 μm while the filler is retained above 150 μm, vibration may force finer particles downward and alter assay uniformity. Granulation or matched particle size fractions reduce this risk. Analytical interference is a separate issue: the strong UV chromophore assists sensitivity, but free iodine or iodide generated during stress may interfere with redox titrations and increase background signals in certain detection systems. HPLC-UV with a reversed-phase C18 column and a pH-controlled phosphate buffer mobile phase is typical in supplier methods; method robustness must be verified according to ICH Q2(R1) because the iodine atom can alter retention and peak symmetry when pH or organic solvent content changes.

The free base generally exhibits limited aqueous solubility; an injectable formulation may require salt formation, pH adjustment with a buffer system, or a co-solvent such as propylene glycol or polyethylene glycol 400 after compatibility screening. For parenteral processing, particulate matter is controlled by USP <788> or Ph. Eur. 2.9.19. Filtration through a 0.22 μm sterilizing-grade membrane is standard for aseptic processing, but membrane compatibility must be verified because low-molecular-weight heterocyclic amines may interact with some filter polymers. Moist heat sterilization at 121 °C for 15 min may be acceptable only when the stability data show no hydrolysis, deiodination, or pH shift; otherwise aseptic filtration is used. The endotoxin limit is calculated from the maximum adult dose according to ICH Q6A and the relevant pharmacopeial monograph; no fixed supplier limit is sufficient for injectable use. Vial and stopper compatibility should be evaluated with the final formulation because iodine-containing substances can promote discoloration in some elastomer closures. Bacterial endotoxin in injectable-grade material is tested by LAL or recombinant Factor C according to the finished product limit; post-filtration filter integrity testing is required for each batch according to the filter manufacturer’s validated bubble point or diffusive flow method.

Elemental Impurity Control, Residual Solvent Limits, and Iodide Release

Elemental impurities are evaluated by ICP-MS using USP <232> and <233> or ICH Q3D Option 1. Because the molecule contains covalently bound iodine, a separate test for ionic iodide, free iodine, or cleaved iodine species may be warranted; aqueous extraction followed by ion chromatography or UV spectrophotometry can distinguish inorganic iodide from organic iodine. A limit for free iodide is derived from safety and stability data and is not harmonized across suppliers. Residual solvents are controlled by headspace gas chromatography per Ph. Eur. 2.4.24 or USP <467>, using Class 1, Class 2, and Class 3 solvent standards relevant to the synthetic route. If the product is dried under reduced pressure, final water content is tested by Karl Fischer USP <921> Method Ic; typical pharma grade material is released with water below 1.0% w/w unless a lower limit is required for a water-sensitive downstream reaction.

Process conflicts arise when moisture, heat, and trace metal residues coexist during granulation or drying. The combination can liberate iodide and produce red-brown discoloration in granulated intermediates. This failure mode is controlled by immediate drying after wet massing, by preventing localized hot spots in the dryer, and by monitoring granule appearance after final blending. For formulations containing carbonate salts or other alkaline excipients, the local pH may deprotonate the 2-amino group and alter dissolution; a binary compatibility study under ICH Q1A(R2) stress at 40 °C/75% RH for 4 weeks is a practical screening step. These controls are risk-management measures based on analogous heteroaromatic amine behavior; published data for this specific configuration is limited.

What Separates 2-Amino-5-iodopyridine from the 5-Bromo and 5-Chloro Analogues?

The 5-iodo derivative has the longest aryl–halogen bond and the lowest carbon–halogen bond dissociation energy among the 5-chloro, 5-bromo, and 5-iodo homologues. This makes it the most reactive in palladium-catalyzed cross-coupling reactions and more prone to reductive deiodination during hydrogenation or prolonged heating in protic solvents. In tablet or capsule manufacturing, the higher molecular density of the iodo compound can increase settling and segregation relative to the lighter bromo and chloro analogues. The 5-bromo homologue is often selected when cost is a limiting factor but coupling reactivity is less demanding. The 5-chloro homologue may be preferred when the final drug product must avoid iodine release and when a lower API bulk density improves blending with standard excipients. Selection among halogenated analogues is therefore driven by synthetic route, coupling efficiency, elemental impurity control, and the physiological target of the final pharmaceutical product. Published comparative formulation data for these specific aminopyridines is limited, so side-by-side compaction and stability screening is recommended before a final salt form or particle grade is fixed.

Protective packaging is mandatory. The product is stored in sealed aluminum-laminated bags or HDPE drums with an inner LDPE liner under dry nitrogen and protected from light. Storage temperatures are usually controlled below 25 °C; stability data for the selected container-closure system must be retained because free iodine can migrate into some polymeric liners at elevated temperatures. When quantities are dispensed into small containers, the new container-closure system is qualified according to USP <661.1> or <661.2>, applicable to the packaging component. The material takes up moisture at high relative humidity; in facilities where relative humidity exceeds 60% RH, pre-drying or nitrogen-purged handling is recommended to maintain water content below the accepted limit. Avoid prolonged exposure to strong reducing agents and to direct sunlight, because both can promote iodine dissociation and discoloration.